Design Therapeutics (DSGN)
NASDAQ:DSGN
Want to see DSGN full AI Analyst Report?
DSGN Stock Chart & Stats
$8.94
-$0.66(-11.15%)
At close: 4:00 PM EST
$8.94
-$0.66(-11.15%)
Day’s Range― - ―
52-Week Range$3.11 - $17.25
Previous CloseN/A
Volume97.34K
Average Volume (3M)213.56K
Market Cap
$830.68M
Enterprise Value$820.64M
Total Cash (Recent Filing)$222.82M
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 10, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding62,456,974
10 Day Avg. Volume267,018
30 Day Avg. Volume213,565
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.53
Price to Sales (P/S)0.00
P/FCF Ratio-9.86
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.19
Forecast
1Y Price Target
$17.00Price Target Upside90.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Formulation Exposure ImprovementAnalyst notes that the DT-216P2 formulation uses the same active drug but substantially improves drug exposure versus the earlier version, addressing a major limitation that previously constrained biological effect.
Pharmacokinetic And Pharmacodynamic ModelingAnalyst pharmacokinetic and pharmacodynamic modeling indicates the improved exposure with the new formulation is likely to translate into larger frataxin increases, de-risking the expected clinical signal and supporting upside if a meaningful biological response is observed.
Platform TechnologyAnalyst highlights that the GeneTAC platform modulates gene expression without permanently altering DNA and supports convenient dosing routes such as injections or oral pills, which could broaden patient access and adherence.
Bears Say
Clinical Outcome UncertaintyAnalyst highlights that transient biological signals and reliance on exposure create uncertainty about translating frataxin increases into meaningful clinical outcomes in pivotal studies.
Exposure-dependent Efficacy RiskAnalyst cautions that prior benefits were closely tied to drug exposure, so insufficient exposure with the new formulation could limit clinical benefit despite proof-of-concept biological signals.
Pharmacokinetic LimitationsAnalyst warns that the earlier formulation produced only temporary frataxin increases and suffered from poor pharmacokinetics, which constrained its effectiveness and could recur if exposure remains inadequate.
Design Therapeutics News
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $3.10 and its highest was $17.25 in the past 12 months.
What is Design Therapeutics’s market cap?
Design Therapeutics’s market cap is $830.68M.
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 98 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on Apr 28, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.317 by $0.027.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 62,456,974 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.317. Following the earnings report the stock price went up 23.263%.
Which hedge fund is a major shareholder of Design Therapeutics?
Currently, no hedge funds are holding shares in DSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Design Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (90.16% Upside)
$17.00 (90.16% Upside)
Blogger Sentiment
Bullish
DSGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.65%
12-Months-Change
Fundamentals
Return on Equity
-33.07%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics (DSGN) is a biotechnology company focused on developing novel therapies for serious degenerative diseases caused by nucleotide repeat expansions. The company operates within the pharmaceutical and biotechnology sectors, leveraging its GeneTAC platform to design small-molecule treatments that target the underlying genetic causes of these diseases. Design Therapeutics aims to address unmet medical needs in conditions such as Friedreich ataxia and other similar genetic disorders.
DSGN Company Deck
DSGN Earnings Call
Q1 2026
0:00 / 0:00
DSGN Stock 12 Month Forecast
Average Price Target
$17.00
▲(90.16% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
16.89% Insiders
5.86% Mutual Funds
0.06% Other Institutional Investors
71.56% Public Companies and
Individual Investors